Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.
DelveInsight’s “Chemotherapy-induced peripheral neuropathy Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chemotherapy-induced peripheral neuropathy, historical and forecasted epidemiology as well as the Chemotherapy-induced peripheral neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some key facts of Chemotherapy-induced peripheral neuropathy Market are:
Request for Sample Report: https://www.delveinsight.com/sample-request/cipn-market
Scope of the Chemotherapy-induced peripheral neuropathy Report
CIPN presents clinically as deficits in sensory, motor, and sometimes autonomic function. Sensory disturbances range from a mild tingling sensation to spontaneous burning pain and hypersensitivity to stimuli.
These symptoms often affect both hands and feet and may spread into a ‘glove/stocking’ distribution. Symptoms are usually symmetrical distally but may be more severe unilaterally.
Although dependent on the specific agent, the feet are often affected first.
There is no sure way to prevent chemo-induced peripheral neuropathy (CIPN), but there are things you can do to manage your symptoms. Treatment can often help ease some of the symptoms of CIPN. Sometimes these symptoms go away a short time after treatment is done. But sometimes they last much longer and need long-term treatment.
Chemotherapy-induced peripheral neuropathy Companies covered:
Chemotherapy-induced peripheral neuropathy Therapies:
Table of Contents:
1. Key Insights
2. Executive Summary of Chemotherapy-induced peripheral neuropathy
3. Competitive Intelligence Analysis for Chemotherapy-induced peripheral neuropathy
4. Chemotherapy-induced peripheral neuropathy: Market Overview at a Glance
4.1. Chemotherapy-induced peripheral neuropathy Total Market Share (%) Distribution in 2017
4.2. Chemotherapy-induced peripheral neuropathy Total Market Share (%) Distribution in 2030
5. Chemotherapy-induced peripheral neuropathy: Disease Background and Overview
6. Patient Journey
7. Chemotherapy-induced peripheral neuropathy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Chemotherapy-induced peripheral neuropathy Treatment and Management
8.2. Chemotherapy-induced peripheral neuropathy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Chemotherapy-induced peripheral neuropathy Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
13. Chemotherapy-induced peripheral neuropathy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Chemotherapy-induced peripheral neuropathy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cipn-market